Kura Oncology, Inc.
KURA
$9.22
-$0.52-5.34%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 18.27M | 17.34M | 20.75M | 15.29M | 14.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.27M | 17.34M | 20.75M | 15.29M | 14.11M |
| Cost of Revenue | 65.53M | 64.47M | 67.91M | 62.79M | 55.97M |
| Gross Profit | -47.26M | -47.13M | -47.16M | -47.50M | -41.87M |
| SG&A Expenses | 31.56M | 39.14M | 32.84M | 25.17M | 22.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 97.08M | 103.60M | 100.75M | 87.95M | 78.81M |
| Operating Income | -78.82M | -86.27M | -80.00M | -72.67M | -64.70M |
| Income Before Tax | -73.33M | -80.93M | -74.12M | -66.12M | -57.20M |
| Income Tax Expenses | 8.00K | 71.00K | -- | -- | 226.00K |
| Earnings from Continuing Operations | -73.33M | -81.00M | -74.12M | -66.12M | -57.43M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.33M | -81.00M | -74.12M | -66.12M | -57.43M |
| EBIT | -78.82M | -86.27M | -80.00M | -72.67M | -64.70M |
| EBITDA | -78.46M | -85.87M | -79.83M | -72.44M | -64.46M |
| EPS Basic | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 |
| Normalized Basic EPS | -0.52 | -0.63 | -0.53 | -0.47 | -0.41 |
| EPS Diluted | -0.83 | -0.92 | -0.85 | -0.75 | -0.66 |
| Normalized Diluted EPS | -0.52 | -0.63 | -0.53 | -0.47 | -0.41 |
| Average Basic Shares Outstanding | 88.61M | 88.05M | 87.65M | 87.59M | 87.42M |
| Average Diluted Shares Outstanding | 88.61M | 88.05M | 87.65M | 87.59M | 87.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |